CA
NTLA icon

Cetera Advisors’s Intellia Therapeutics NTLA Stock Holding History

Cetera Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,321
Closed -$446K – 1502
2021
Q3 		$446K Buy
+3,321
New +$503K 0.01% 920

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cetera Advisors's NTLA Position: Q4 2021 in Review

Cetera Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 3,321 shares — an estimated $446K sold.

Cetera Advisors first reported a position in NTLA in Q3 2021 and held it in 1 quarter. The position peaked at $446K in Q3 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • Cetera Advisors reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cetera Advisors sold 3,321 Intellia Therapeutics shares in Q4 2021, an estimated $446K.
  • Cetera Advisors first reported a position in Intellia Therapeutics in Q3 2021 and held it in 1 quarter.
  • Cetera Advisors's Intellia Therapeutics position peaked at $446K in Q3 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Cetera Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.